Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.71 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.71 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.45 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.45 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414665 | 0.81 | GRIN2C (0.64) | GRIN2CNPSR1LMNAKMT2AMAPT | |
| SCHEMBL4413282 | 0.78 | CA1 (0.49) | HTTNCOA1SMN1; SMN2NCOA3LMNA | |
| SCHEMBL4422031 | 0.75 | KMT2A (0.56) | HTTNCOA1SMN1; SMN2NCOA3GRIN2C | |
| SCHEMBL7902279 | 0.75 | GRIN2C (1.00) | HTTNCOA1SMN1; SMN2NCOA3GRIN2C | |
| SCHEMBL4416142 | 0.75 | GRIN2C (0.55) | GRIN2CKMT2AMTNR1B | |
| SCHEMBL4423041 | 0.73 | GRIN2C (0.54) | GRIN2CKMT2AMTNR1B | |
| SCHEMBL30914581 | 0.72 | MAPK1 (0.65) | HTTNCOA1SMN1; SMN2NCOA3GRIN2C | |
| SCHEMBL1219835 | 0.71 | SMN1; SMN2 (0.72) | HTTNCOA1SMN1; SMN2NCOA3GRIN2C | |
| SCHEMBL4416149 | 0.69 | MTNR1B (0.45) | SMN1; SMN2GRIN2CKMT2AMTNR1BRXFP1 | |
| SCHEMBL7894638 | 0.69 | GRIN2C (1.00) | GRIN2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663983-B1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2009-01-21 | — | — | EP | disclosed |
| EP-1663983-A1 | N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2006-06-07 | — | — | EP | disclosed |
| US-20050070570-A1 | Novel potassium channels modulators | 4SC AG (DE) | 2005-03-31 | — | — | US | disclosed |
| WO-2004113302-A1 | N-SUBSTITUTED 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS | 4SC AG (DE) | 2004-12-29 | — | — | WO | disclosed |
| EP-1489071-A1 | N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators | 4SC AG (DE) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070570-A1 | Novel potassium channels modulators | HCN4, KCNA4, KCNN4 | HTT 1037/4885NCOA1 1192/4885SMN1; SMN2 4121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.